Clinical trials: Eye Inflammation
Corneal Neovascularization
Corneal Crosslinking for Treatment of Corneal Neovascularization
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
- Trial name
- NCT04787471
- Testing
- 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Price Vision Group
Cataract
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
- Trial name
- NCT00333255
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Alcon Research
Inflammation, Pain
Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects…
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02329743
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- A.T. Resolve SARL
Inflammation and Pain Following Ocular Surgery
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
- Trial name
- NCT02065375
- Testing
- Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Biogen
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis
Cataracts, Inflammation
Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery
The primary objective of this study was to compare the safety and efficacy of Durezol™ compared to Pred Forte™ for the treatment of inflammation following cataract surgery in a pediatric population 0 to 3 years of age.
- Trial name
- NCT01124045
- Testing
- Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Cataract
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.
- Trial name
- PRO-145/III (NCT03693989)
- Testing
- Difluprednate 0.05%, Prednefrin
- Where
- 5 sites in Mexico
- Volunteers
- 178 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Intraocular Inflammation, Suspected Endophthalmitis
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Specific study objectives include: To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually).
- Trial name
- NCT05791695
- Testing
- Non Applicable
- Where
- United States
- Volunteers
- 155,413 people
- Sponsor
- Regeneron Pharmaceuticals
Cataract, Pain
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
- Conditions
- Cataract, Pain, Ocular Inflammation
- Trial name
- NCT02786901
- Testing
- Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
- Where
- 6 sites in United States
- Volunteers
- 600 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
The purpose of this study is to demonstrate the non-inferiority of the study treatment (combined levofloxacin + dexamethasone eye drops) followed by dexamethasone eye drops alone vs.
- Trial name
- LEADER7 (NCT03739528)
- Testing
- Levofloxacin + dexamethasone followed by dexamethasone, Tobramycin + Dexamethasone
- Where
- 57 sites in Italy
- Volunteers
- 808 people
- Sponsor
- NTC srl
Inflammation Eye
A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease…
- Trial name
- NCT03687931
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- iDrop, Inc.
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-1 (NCT04246801)
- Testing
- Clobetasol propionate, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- Salvat
Posterior Blepharoconjunctivitis
A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers.
- Trial name
- NCT01220258
- Testing
- Azithromycin ophthalmic solution, 1%
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Inflammation Symptoms, Eye Dryness
A Clinical Trial to Evaluate the Efficacy of an Oral Supplement in Supporting Vision and Eye Health
This study aims to evaluate the efficacy of BioNatureHealth's Eye Empower supplement in supporting vision and eye health. It is a virtual, single-group trial lasting 3 weeks.
- Conditions
- Inflammation Symptoms, Eye Dryness, Eye Health
- Trial name
- NCT06515457
- Testing
- Eye Empower
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bio Nature Health
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Cataract, Inflammation
Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery
This study is being conducted to show that indomethacin is at least as effective as ketorolac for the prevention of ocular inflammation following cataract surgery.
- Trial name
- NCT00904904
- Testing
- Indomethacin ophthalmic solution, Ketorolac Ophthalmic Solution
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Bausch & Lomb Incorporated
Behcet Disease
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.
- Trial name
- Behcet (NCT02756650)
- Testing
- Canakinumab
- Where
- Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Cataract
Confirmatory Study Nepafenac 0.3%
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01109173
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle
- Where
- United States
- Volunteers
- 2,120 people
- Sponsor
- Alcon Research
Cataract
Nepafenac 0.3% Two Study
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01318499
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Alcon Research